Your browser doesn't support javascript.
loading
Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields.
Gorman, Jason; Mason, Rosemarie D; Nettey, Leonard; Cavett, Nicole; Chuang, Gwo-Yu; Peng, Dongjun; Tsybovsky, Yaroslav; Verardi, Raffaello; Nguyen, Richard; Ambrozak, David; Biris, Kristin; LaBranche, Celia C; Ramesh, Akshaya; Schramm, Chaim A; Zhou, Jing; Bailer, Robert T; Kepler, Thomas B; Montefiori, David C; Shapiro, Lawrence; Douek, Daniel C; Mascola, John R; Roederer, Mario; Kwong, Peter D.
Affiliation
  • Gorman J; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Mason RD; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Nettey L; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Cavett N; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Chuang GY; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Peng D; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Tsybovsky Y; Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
  • Verardi R; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Nguyen R; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Ambrozak D; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Biris K; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • LaBranche CC; Duke Human Vaccine Institute, Duke University School of Medicine, Duke University, Durham, NC 27710, USA.
  • Ramesh A; Boston University School of Medicine, Boston University, Boston, MA 02118, USA.
  • Schramm CA; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Zhou J; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Bailer RT; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Kepler TB; Boston University School of Medicine, Boston University, Boston, MA 02118, USA.
  • Montefiori DC; Duke Human Vaccine Institute, Duke University School of Medicine, Duke University, Durham, NC 27710, USA.
  • Shapiro L; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA.
  • Douek DC; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Mascola JR; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
  • Roederer M; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: roederer@nih.gov.
  • Kwong PD; Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: pdkwong@nih.gov.
Immunity ; 51(4): 724-734.e4, 2019 10 15.
Article de En | MEDLINE | ID: mdl-31586542
ABSTRACT
HIV- and SIV-envelope (Env) trimers are both extensively glycosylated, and antibodies identified to date have been unable to fully neutralize SIVmac239. Here, we report the isolation, structure, and glycan interactions of antibody ITS90.03, a monoclonal antibody that completely neutralized the highly neutralization-resistant isolate, SIVmac239. The co-crystal structure of a fully glycosylated SIVmac239-gp120 core in complex with rhesus CD4 and the antigen-binding fragment of ITS90.03 at 2.5-Å resolution revealed that ITS90 recognized an epitope comprised of 45% glycan. SIV-gp120 core, rhesus CD4, and their complex could each be aligned structurally to their human counterparts. The structure revealed that glycans masked most of the SIV Env protein surface, with ITS90 targeting a glycan hole, which is occupied in ∼83% of SIV strains by glycan N238. Overall, the SIV glycan shield appears to functionally resemble its HIV counterpart in coverage of spike, shielding from antibody, and modulation of receptor accessibility.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Polyosides / Infections à VIH / Syndrome d'immunodéficience acquise du singe / VIH (Virus de l'Immunodéficience Humaine) / Virus de l'immunodéficience simienne / Anticorps neutralisants / Anticorps monoclonaux Limites: Animals / Humans Langue: En Journal: Immunity Sujet du journal: ALERGIA E IMUNOLOGIA Année: 2019 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Polyosides / Infections à VIH / Syndrome d'immunodéficience acquise du singe / VIH (Virus de l'Immunodéficience Humaine) / Virus de l'immunodéficience simienne / Anticorps neutralisants / Anticorps monoclonaux Limites: Animals / Humans Langue: En Journal: Immunity Sujet du journal: ALERGIA E IMUNOLOGIA Année: 2019 Type de document: Article Pays d'affiliation: États-Unis d'Amérique
...